Myeloid-derived suppressor cell role in tumor-related inflammation

Cancer Letters

Volumn 267, Issue 2, 2008, Pages 216-225

  Dolcetti, Luigi ^a,b   Marigo, Ilaria ^a,b   Mantelli, Barbara ^a,b   Peranzoni, Elisa ^a   Zanovello, Paola ^a,c   Bronte, Vincenzo ^c  

^a Department of Oncology and Surgical Sciences ^*  (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Arginine metabolism; Cancer; Immune suppression; Inflammation; MDSC; Myeloid cells; NO

Indexed keywords

ARGININE;

BONE MARROW CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; HUMAN; IMMUNOLOGICAL TOLERANCE; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SUPPRESSOR CELL;

EID: 47749094603     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.012     Document Type: Review

References (101)

1. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol. 16 (2006) 38-52
2. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
3. Krishnamoorthy S., and Honn K.V. Inflammation and disease progression. Cancer Metastasis Rev. 25 (2006) 481-491
4. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., and Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 67 (2007) 425 (author reply 426)
5. Bronte V., Wang M., Overwijk W.W., Surman D.R., Pericle F., Rosenberg S.A., and Restifo N.P. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161 (1998) 5313-5320
6. Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S., and Bronte V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116 (2006) 2777-2790
7. Cauley L.S., Miller E.E., Yen M., and Swain S.L. Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma. J. Immunol. 165 (2000) 6056-6066
8. Schleifer K.W., and Mansfield J.M. Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J. Immunol. 151 (1993) 5492-5503
9. al-Ramadi B.K., Brodkin M.A., Mosser D.M., and Eisenstein T.K. Immunosuppression induced by attenuated Salmonella. Evidence for mediation by macrophage precursors. J. Immunol. 146 (1991) 2737-2746
10. Angulo I., Jimenez-Diaz M.B., Garcia-Bustos J.F., Gargallo D., de las Heras F.G., Munoz-Fernandez M.A., and Fresno M. Candida albicans infection enhances immunosuppression induced by cyclophosphamide by selective priming of suppressive myeloid progenitors for NO production. Cell. Immunol. 218 (2002) 46-58
11. Tsuda Y., Takahashi H., Kobayashi M., Hanafusa T., Herndon D.N., and Suzuki F. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 21 (2004) 215-226
12. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., and Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179 (2007) 977-983
13. Bronte V., Cingarlini S., Marigo I., De Santo C., Gallina G., Dolcetti L., Ugel S., Peranzoni E., Mandruzzato S., and Zanovello P. Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol. Invest. 35 (2006) 327-357
14. Sinha P., Clements V.K., and Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174 (2005) 636-645
15. Salvadori S., Martinelli G., and Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol. 164 (2000) 2214-2220
16. Melani C., Chiodoni C., Forni G., and Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102 (2003) 2138-2145
17. Hamilton J.A. GM-CSF in inflammation and autoimmunity. Trends Immunol. 23 (2002) 403-408
18. Dranoff G. GM-CSF-based cancer vaccines. Immunol. Rev. 188 (2002) 147-154
19. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., and Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64 (2004) 6337-6343
20. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., and Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18 (2007) 226-232
21. Rossner S., Voigtlander C., Wiethe C., Hanig J., Seifarth C., and Lutz M.B. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur. J. Immunol. 35 (2005) 3533-3544
22. Obermueller E., Vosseler S., Fusenig N.E., and Mueller M.M. Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res. 64 (2004) 7801-7812
23. Wislez M., Fleury-Feith J., Rabbe N., Moreau J., Cesari D., Milleron B., Mayaud C., Antoine M., Soler P., and Cadranel J. Tumor-derived granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype pulmonary adenocarcinoma. Am. J. Pathol. 159 (2001) 1423-1433
24. Rochet N., Dubousset J., Mazeau C., Zanghellini E., Farges M.F., de Novion H.S., Chompret A., Delpech B., Cattan N., Frenay M., and Gioanni J. Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). Int. J. Cancer 82 (1999) 282-285
25. Mueller M.M., Peter W., Mappes M., Huelsen A., Steinbauer H., Boukamp P., Vaccariello M., Garlick J., and Fusenig N.E. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am. J. Pathol. 159 (2001) 1567-1579
26. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., and Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66 (2006) 1123-1131
27. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., and Blay J.Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92 (1998) 4778-4791
28. Lin E.Y., Gouon-Evans V., Nguyen A.V., and Pollard J.W. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia 7 (2002) 147-162
29. Rambaldi A., Wakamiya N., Vellenga E., Horiguchi J., Warren M.K., Kufe D., and Griffin J.D. Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J. Clin. Invest. 81 (1988) 1030-1035
30. Haran-Ghera N., Krautghamer R., Lapidot T., Peled A., Dominguez M.G., and Stanley E.R. Increased circulating colony-stimulating factor-1 (CSF-1) in SJL/J mice with radiation-induced acute myeloid leukemia (AML) is associated with autocrine regulation of AML cells by CSF-1. Blood 89 (1997) 2537-2545
31. Gerharz C.D., Reinecke P., Schneider E.M., Schmitz M., and Gabbert H.E. Secretion of GM-CSF and M-CSF by human renal cell carcinomas of different histologic types. Urology 58 (2001) 821-827
32. Champelovier P., Boucard N., Levacher G., Simon A., Seigneurin D., and Praloran V. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol. Res. 30 (2002) 301-309
33. Tanaka J., Miyake T., Shimizu T., Wakayama T., Tsumori M., Koshimura K., Murakami Y., and Kato Y. Effect of continuous subcutaneous administration of a low dose of G-CSF on stem cell mobilization in healthy donors: a feasibility study. Int. J. Hematol. 75 (2002) 489-492
34. Clark S.C., and Kamen R. The human hematopoietic colony-stimulating factors. Science 236 (1987) 1229-1237
35. Tsukuda M., Nagahara T., Yago T., Matsuda H., and Yanoma S. Production of granulocyte colony-stimulating factor by head and neck carcinomas. Biotherapy 6 (1993) 183-187
36. Ota S., Kato A., Kobayashi H., Yonezumi M., Yamaguchi J., Musashi M., Imamura M., and Asaka M. Monoclonal origin of an esophageal carcinosarcoma producing granulocyte-colony stimulating factor: a case report. Cancer 82 (1998) 2102-2111
37. Ichiishi E., Yoshikawa T., Kogawa T., Yoshida N., and Kondo M. Possible paracrine growth of adenocarcinoma of the stomach induced by granulocyte colony stimulating factor produced by squamous cell carcinoma of the oesophagus. Gut 46 (2000) 432-434
38. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., and Carbone D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998) 4150-4166
39. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4 (2004) 941-952
40. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., and Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 (2004) 409-421
41. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., and Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004) 677-686
42. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G.M., and Feng Z.H. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 252 (2007) 86-92
43. Pan P.Y., Wang G.X., Yin B., Ozao J., Ku T., Divino C.M., and Chen S.H. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111 (2008) 219-228
44. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., and Moses H.L. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13 (2008) 23-35
45. Mantovani A., Sozzani S., Locati M., Allavena P., and Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 (2002) 549-555
46. Bronte V., and Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 5 (2005) 641-654
47. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., and Berzofsky J.A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1 (2000) 515-520
48. Terabe M., Park J.M., and Berzofsky J.A. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol. Immunother. 53 (2004) 79-85
49. Ambrosino E., Terabe M., Halder R.C., Peng J., Takaku S., Miyake S., Yamamura T., Kumar V., and Berzofsky J.A. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J. Immunol. 179 (2007) 5126-5136
50. Bunt S.K., Sinha P., Clements V.K., Leips J., and Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176 (2006) 284-290
51. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
52. Sinha P., Clements V.K., Fulton A.M., and Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67 (2007) 4507-4513
53. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., and Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67 (2007) 10019-10026
54. Park S.J., Nakagawa T., Kitamura H., Atsumi T., Kamon H., Sawa S., Kamimura D., Ueda N., Iwakura Y., Ishihara K., Murakami M., and Hirano T. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173 (2004) 3844-3854
55. Geissmann F., Jung S., and Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 (2003) 71-82
56. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., Herber D.L., Schneck J., and Gabrilovich D.I. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13 (2007) 828-835
57. Schluns K.S., and Lefrancois L. Cytokine control of memory T-cell development and survival. Nat. Rev. Immunol. 3 (2003) 269-279
58. Whitmire J.K., Tan J.T., and Whitton J.L. Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection. J. Exp. Med. 201 (2005) 1053-1059
59. Refaeli Y., Van Parijs L., Alexander S.I., and Abbas A.K. Interferon gamma is required for activation-induced death of T lymphocytes. J. Exp. Med. 196 (2002) 999-1005
60. Sercan O., Hammerling G.J., Arnold B., and Schuler T. Innate immune cells contribute to the IFN-gamma-dependent regulation of antigen-specific CD8+ T cell homeostasis. J. Immunol. 176 (2006) 735-739
61. Badovinac V.P., Porter B.B., and Harty J.T. CD8+ T cell contraction is controlled by early inflammation. Nat. Immunol. 5 (2004) 809-817
62. Badovinac V.P., Porter B.B., and Harty J.T. Programmed contraction of CD8(+) T cells after infection. Nat. Immunol. 3 (2002) 619-626
63. Vig M., Srivastava S., Kandpal U., Sade H., Lewis V., Sarin A., George A., Bal V., Durdik J.M., and Rath S. Inducible nitric oxide synthase in T cells regulates T cell death and immune memory. J. Clin. Invest. 113 (2004) 1734-1742
64. Laniewski N.G., and Grayson J.M. Antioxidant treatment reduces expansion and contraction of antigen-specific CD8+ T cells during primary but not secondary viral infection. J. Virol. 78 (2004) 11246-11257
65. Hildeman D.A., Mitchell T., Teague T.K., Henson P., Day B.J., Kappler J., and Marrack P.C. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 10 (1999) 735-744
66. Hildeman D.A., Mitchell T., Aronow B., Wojciechowski S., Kappler J., and Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc. Natl. Acad. Sci. USA 100 (2003) 15035-15040
67. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2 (2001) 907-916
68. Rodriguez P.C., Quiceno D.G., and Ochoa A.C. l-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109 (2007) 1568-1573
69. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., Antonia S., Ochoa J.B., and Ochoa A.C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64 (2004) 5839-5849
70. Rodriguez P.C., Zea A.H., DeSalvo J., Culotta K.S., Zabaleta J., Quiceno D.G., Ochoa J.B., and Ochoa A.C. l-Arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171 (2003) 1232-1239
71. Bingisser R.M., Tilbrook P.A., Holt P.G., and Kees U.R. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160 (1998) 5729-5734
72. Duhe R.J., Evans G.A., Erwin R.A., Kirken R.A., Cox G.W., and Farrar W.L. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc. Natl. Acad. Sci. USA 95 (1998) 126-131
73. Fischer T.A., Palmetshofer A., Gambaryan S., Butt E., Jassoy C., Walter U., Sopper S., and Lohmann S.M. Activation of cGMP-dependent protein kinase Ibeta inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells. J. Biol. Chem. 276 (2001) 5967-5974
74. Bronte V., Serafini P., De Santo C., Marigo I., Tosello V., Mazzoni A., Segal D.M., Staib C., Lowel M., Sutter G., Colombo M.P., and Zanovello P. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170 (2003) 270-278
75. Szabo C., Ischiropoulos H., and Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 6 (2007) 662-680
76. Xia Y., Roman L.J., Masters B.S., and Zweier J.L. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J. Biol. Chem. 273 (1998) 22635-22639
77. Xia Y., and Zweier J.L. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. USA 94 (1997) 6954-6958
78. Ochoa A.C., Zea A.H., Hernandez C., and Rodriguez P.C. Arginase prostaglandins and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13 (2007) 721s-726s
79. Kusmartsev S., Nefedova Y., Yoder D., and Gabrilovich D.I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172 (2004) 989-999
80. Kusmartsev S., and Gabrilovich D.I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74 (2003) 186-196
81. De Santo C., Serafini P., Marigo I., Dolcetti L., Bolla M., Del Soldato P., Melani C., Guiducci C., Colombo M.P., Iezzi M., Musiani P., Zanovello P., and Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. USA 102 (2005) 4185-4190
82. Kusmartsev S., and Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174 (2005) 4880-4891
83. Liu C., Yu S., Kappes J., Wang J., Grizzle W.E., Zinn K.R., and Zhang H.G. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109 (2007) 4336-4342
84. Yanagisawa K., Exley M.A., Jiang X., Ohkochi N., Taniguchi M., and Seino K. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Cancer Res. 66 (2006) 11441-11446
85. De Palma M., and Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim. Biophys. Acta 1766 (2006) 159-166
86. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., Blanchard D., Bais C., Peale F.V., van Bruggen N., Ho C., Ross J., Tan M., Carano R.A., Meng Y.G., and Ferrara N. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450 (2007) 825-831
87. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., and Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25 (2007) 911-920
88. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., and Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8 (2005) 211-226
89. Bronte V., Chappell D.B., Apolloni E., Cabrelle A., Wang M., Hwu P., and Restifo N.P. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162 (1999) 5728-5737
90. Seung L.P., Rowley D.A., Dubey P., and Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. USA 92 (1995) 6254-6258
91. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., Letterio J.J., Paul W.E., and Berzofsky J.A. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198 (2003) 1741-1752
92. Brito C., Naviliat M., Tiscornia A.C., Vuillier F., Gualco G., Dighiero G., Radi R., and Cayota A.M. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J. Immunol. 162 (1999) 3356-3366
93. Ohshima H., Tatemichi M., and Sawa T. Chemical basis of inflammation-induced carcinogenesis. Arch. Biochem. Biophys. 417 (2003) 3-11
94. Ulrich C.M., Bigler J., and Potter J.D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer 6 (2006) 130-140
95. Mariotto S., Cuzzolin L., Adami A., Del Soldato P., Suzuki H., and Benoni G. Effect of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils. Br. J. Pharmacol. 115 (1995) 225-226
96. Fiorucci S., and Del Soldato P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig. Liver Dis. 35 Suppl. 2 (2003) S9-S19
97. Fiorucci S., Santucci L., Gresele P., Faccino R.M., Del Soldato P., and Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 124 (2003) 600-607
98. Perez G.M., Melo M., Keegan A.D., and Zamorano J. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J. Immunol. 168 (2002) 1428-1434
99. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., and Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203 (2006) 2691-2702
100. Young M.R., Halpin J., Hussain R., Lozano Y., Djordjevic A., Devata S., Matthews J.P., and Wright M.A. Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis. Invas. Metastasis 13 (1993) 169-177
101. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., and Gabrilovich D. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63 (2003) 4441-4449